Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.

Joao Pedro FerreiraFaiez ZannadMilton PackerGerasimos FilippatosStuart J PocockFrancisco Vasques-NóvoaMichael BöhmJaved ButlerStefan Anker

Published in: European journal of heart failure (2024)

In EMPEROR-Preserved, LRTI was frequent and associated with a poor prognosis. Empagliflozin was associated with a reduced risk of LRTI compared to placebo.

Keyphrases

poor prognosis
ejection fraction
respiratory tract
heart failure
long non coding rna
aortic stenosis
left ventricular
randomized controlled trial
clinical trial
phase iii
aortic valve
acute heart failure
cardiac resynchronization therapy
study protocol
placebo controlled